Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome-first-in-human pilot study

Tomoyoshi Tamura; Kei Hayashida; Motoaki Sano; Masaru Suzuki; Takayuki Shibusawa; Joe Yoshizawa; Yosuke Kobayashi; Takeshi Suzuki; Shigeo Ohta; Hiroshi Morisaki; Keiichi Fukuda; Shingo Hori

doi:10.1253/circj.CJ-16-0127

Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome-first-in-human pilot study

Tomoyoshi Tamura, Kei Hayashida, Motoaki Sano, Masaru Suzuki, Takayuki Shibusawa, Joe Yoshizawa, Yosuke Kobayashi, Takeshi Suzuki, Shigeo Ohta, Hiroshi Morisaki, Keiichi Fukuda, Shingo Hori

Gastrointestinal Surgery

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

Background: Hydrogen gas inhalation (HI) ameliorates cerebral and cardiac dysfunction in animal models of postcardiac arrest syndrome (PCAS). HI for human patients with PCAS has never been studied. Methods and Results: Between January 2014 and January 2015, 21 of 107 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. After excluding 16 patients with specific criteria, 5 patients underwent HI together with target temperature management (TTM). No undesirable effects attributable to HI were observed and 4 patients survived 90 days with a favorable neurological outcome. Conclusions: HI in combination with TTM is a feasible therapy for patients with PCAS.

Original language	English
Pages (from-to)	1870-1873
Number of pages	4
Journal	Circulation Journal
Volume	80
Issue number	8
DOIs	https://doi.org/10.1253/circj.CJ-16-0127
Publication status	Published - 2016

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-16-0127

Cite this

@article{293267e0c1d34cdab74eb13603f0693e,

title = "Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome-first-in-human pilot study",

abstract = "Background: Hydrogen gas inhalation (HI) ameliorates cerebral and cardiac dysfunction in animal models of postcardiac arrest syndrome (PCAS). HI for human patients with PCAS has never been studied. Methods and Results: Between January 2014 and January 2015, 21 of 107 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. After excluding 16 patients with specific criteria, 5 patients underwent HI together with target temperature management (TTM). No undesirable effects attributable to HI were observed and 4 patients survived 90 days with a favorable neurological outcome. Conclusions: HI in combination with TTM is a feasible therapy for patients with PCAS.",

author = "Tomoyoshi Tamura and Kei Hayashida and Motoaki Sano and Masaru Suzuki and Takayuki Shibusawa and Joe Yoshizawa and Yosuke Kobayashi and Takeshi Suzuki and Shigeo Ohta and Hiroshi Morisaki and Keiichi Fukuda and Shingo Hori",

year = "2016",

doi = "10.1253/circj.CJ-16-0127",

language = "English",

volume = "80",

pages = "1870--1873",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "8",

}

TY - JOUR

T1 - Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome-first-in-human pilot study

AU - Tamura, Tomoyoshi

AU - Hayashida, Kei

AU - Sano, Motoaki

AU - Suzuki, Masaru

AU - Shibusawa, Takayuki

AU - Yoshizawa, Joe

AU - Kobayashi, Yosuke

AU - Suzuki, Takeshi

AU - Ohta, Shigeo

AU - Morisaki, Hiroshi

AU - Fukuda, Keiichi

AU - Hori, Shingo

PY - 2016

Y1 - 2016

N2 - Background: Hydrogen gas inhalation (HI) ameliorates cerebral and cardiac dysfunction in animal models of postcardiac arrest syndrome (PCAS). HI for human patients with PCAS has never been studied. Methods and Results: Between January 2014 and January 2015, 21 of 107 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. After excluding 16 patients with specific criteria, 5 patients underwent HI together with target temperature management (TTM). No undesirable effects attributable to HI were observed and 4 patients survived 90 days with a favorable neurological outcome. Conclusions: HI in combination with TTM is a feasible therapy for patients with PCAS.

AB - Background: Hydrogen gas inhalation (HI) ameliorates cerebral and cardiac dysfunction in animal models of postcardiac arrest syndrome (PCAS). HI for human patients with PCAS has never been studied. Methods and Results: Between January 2014 and January 2015, 21 of 107 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. After excluding 16 patients with specific criteria, 5 patients underwent HI together with target temperature management (TTM). No undesirable effects attributable to HI were observed and 4 patients survived 90 days with a favorable neurological outcome. Conclusions: HI in combination with TTM is a feasible therapy for patients with PCAS.

UR - http://www.scopus.com/inward/record.url?scp=84982292598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982292598&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-16-0127

DO - 10.1253/circj.CJ-16-0127

M3 - Article

C2 - 27334126

AN - SCOPUS:84982292598

SN - 1346-9843

VL - 80

SP - 1870

EP - 1873

JO - Circulation Journal

JF - Circulation Journal

IS - 8

ER -

Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome-first-in-human pilot study

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this